EUVIMEDEUVIMED entdecken
Crossref

Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study

Louis Oudiane iD, Massinissa Benyahia, Florian Salipante, Adeline Dubois, Laurent Muller, Jean-Philippe Lavigne, Alix Pantel, Claire Roger iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Louis Oudiane und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Anesthesia and Critical Care, Pain and Emergency Medicine, UR-UM103 IMAGINE, Univ Montpellier, Nîmes University Hospital, Montpellier, Pl…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Gram-Negative Bacterial Infections, Bacteremia, Gram-Negative Bacteria. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: bioMérieux.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rapid diagnostic tools (RDT), together with rapid antimicrobial susceptibility testing (rAST), have emerged as means to shorten the time to pathogen identification and AST for bloodstream infections (BSI). Whether these techniques significantly impact antimicrobial therapy in critically ill patients with BSI remains to be determined.

Methods

A single-center quasi-experimental study comparing antibiotic optimisation before and after the implementation of innovative RDT, BIOFIRE® Blood Culture Identification 2 (BCID2) Panel and VITEK® REVEALTM (bioMérieux), was conducted. All adult patients admitted to the intensive care unit (ICU) with a first episode of Gram-Negative Bacilli BSI were included in the study. The primary outcome was the proportion of patients receiving optimized antibiotic therapy within 24 h of blood culture incubation.

Results

A total of 100 patients, 50 in each study period, were included. The proportion of patients receiving optimized antibiotic therapy within 24 h of blood culture incubation was not significantly different in the post-interventional (28%) compared with the pre-interventional group (20%) (P = 0.3). When considering antibiotic therapy optimisation within 24 h of positive blood culture, the proportion of patients with optimized antibiotic therapy was significantly higher in the post-intervention group (46% versus 26%, P = 0.037). The time to optimisation in the RDT group was shorter than in the conventional group, 27 h versus 46 h, respectively (P < 0.001).

Conclusions

The real-world implementation of RDT significantly shortened time to results but did not improve antibiotic therapy optimisation within 24 h of blood culture incubation. An antimicrobial stewardship programme could help enhance the clinical impact of RDT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsGram-Negative Bacterial InfectionsBacteremiaGram-Negative BacteriaHumansCritical IllnessMaleFemaleMiddle AgedAgedMicrobial Sensitivity TestsIntensive Care UnitsBlood CultureAdultTime Factors

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Anesthesia and Critical Care, Pain and Emergency Medicine, UR-UM103 IMAGINE, Univ Montpellier, Nîmes University Hospital, Montpellier, Place du Professeur Robert Debré, 30 029 Nîmes Cedex 9, France.
  • Department of Microbiology and Hospital Hygiene, INSERM U1047 VBIC, Univ Montpellier, Nîmes University Hospital, Nîmes, France.
  • Department of Biostatistics, Epidemiology, Public Health, and Innovation in Methodology (BESPIM), Nîmes University Hospital, Nîmes, France.

ORCID-Profile: Louis Oudiane, Claire Roger

Förderung

  • bioMérieux

Zitieren

APA

Oudiane, L., Benyahia, M., Salipante, F., Dubois, A., Muller, L., Lavigne, J. P., Pantel, A., & Roger, C. (2025). Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf271

Vancouver

Oudiane L, Benyahia M, Salipante F, Dubois A, Muller L, Lavigne JP, et al. Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf271

BibTeX
@article{Oudiane2025,
  author = {Oudiane, Louis and Benyahia, Massinissa and Salipante, Florian and Dubois, Adeline and Muller, Laurent and Lavigne, Jean-Philippe and Pantel, Alix and Roger, Claire},
  title = {Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf271}
}
Kostenlos starten →